Granules India Acquires Senn Chemicals to Expand into Peptide Therapeutics
The Indian pharmaceutical company will leverage Senn’s existing business and relationships to advance its expansion into the CDMO segment.
Pharmaceutical company, Granules India, has announced the closure of its acquisition of Swiss CDMO, Senn Chemicals AG, through its subsidiary, Granules Peptides (1). Through this acquisition, the Indian pharmaceutical company will enter the peptide therapeutics sector and the CDMO space.
Senn is a CDMO that focuses on custom peptide manufacturing, offering clients support from early development to commercial production. The company has built up a reputation, since it was founded in 1963, as a specialist in liquid-phase peptide synthesis and solid-phase peptide synthesis across the pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets.
“The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organization. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialized CDMO capabilities, we are well-positioned to deliver high-quality, next-generation treatments,” said Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, in the press release (1). “Senn’s specialized expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space.”
With the acquisition, Granules will be able to speed up its development and manufacture of glucagon-like peptide-1 receptor agonists as well as other peptide-based APIs. Through these new capabilities, the company will be better positioned to meet the growing demand being seen in the anti-diabetic, anti-obesity, and other next-generation therapeutic areas.
“We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation,” remarked Dr. Rico Wiedenbruch, Chairman, Senn Chemicals AG, in a press release announcing the signing of the definitive share purchase agreement (2). “With Granules’ scale, operational efficiency, and global reach in pharmaceuticals industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics. This partnership strengthens our ability to serve our customers with best-in-class CDMO solutions while driving innovation in peptide development and manufacturing."
Under the terms of acquisition, Senn and its operations in Dielsdorf, Switzerland, which includes the ISO 9001:2015 certified manufacturing facility that is approved for current good manufacturing practice production by Swissmedic, will work under Granules’ ownership. A commitment to maintain Senn’s scientific excellence and customer focus has been made by Granules.
The acquisition has been reportedly completed for CHF 20 million (USD 22 million) (3).
References
Granules India. Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services. Press Release, April 10, 2025.
Granules India. Granules India Enters the High Growing Peptide Ssegment and CDMO Business by Acquiring Senn Chemicals AG. Press Release, Feb. 21, 2025.
Singh, A. Granules India Completes Acquisition of Swiss CDMO Senn Chemicals AG. Business Standard, April 10, 2025.